IMR Press / EJGO / Volume 39 / Issue 5 / DOI: 10.12892/ejgo4019.2018

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Case Report
Complete response after “neoadjuvant” pertuzumab + trastuzumab + docetaxel chemotherapy in Her2-positive breast cancer
Show Less
1 Oncology Unit Gard Cancer Institute, Nîmes, France
Eur. J. Gynaecol. Oncol. 2018, 39(5), 836–837; https://doi.org/10.12892/ejgo4019.2018
Published: 10 October 2018
Abstract

It is well demonstrated that Her-2 positive breast cancer patients have more aggressive disease, with a poor prognosis. The author report the case of a 50-year-old Caucasian woman, diagnosed with a seven-centimeter right breast cancer. Biospy core revealed a Her-2 positive, positive for hormonal receptors, ki67 at 70%, breast invasive ductal carcinoma, associated with right axillary adenomegalies. Positron emission tomography scan showed diffuse metastatic adenomegalies upper and under the diaphragm and a 55×55 mm lesion in the right breast. The patient began chemotherapy with docetaxel+pertuzumab+trastuzumab regimen. After three courses, all the positron emission tomography scans did not show any pathological hypermetabolism and the primitive lesion was measured at 16×18 mm. It was decided to perform a right mastectomy. The patient will then follow maintenance with pertuzumab and trastuzumab, in combination with hormonotherapy.
Keywords
Her2 breast cancer
Pertuzumab
Metastatic breast cancer
Her2-targeted therapies
Share
Back to top